
IBSA UK launches non-hormonal injectable for menopausal vulvovaginal symptoms
A next-generation hyaluronic acid treatment designed to improve sexual and genital symptoms of GSM Watford, UK. February 2nd 2026 – IBSA UK, the UK subsidiary of Swiss pharmaceutical company IBSA, today announces the launch of Hyaluxelle®, a non-hormonal hyaluronic acid treatment indicated for adult women to treat vulvar vestibule atrophic
